Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision Medicine for Lipids: The New US Guidelines for Dyslipidemia.

Clinical chemistry·2026
Same author

Establishment and functional analysis of an inducible Apoc2-knockout mouse model to investigate the role of Apoc2 in normal hematopoiesis.

Lab animal·2026
Same author

Measurement of low-density lipoprotein cholesterol and other circulating lipids in Brazil: a systematic literature review.

Clinica chimica acta; international journal of clinical chemistry·2026
Same author

High-Density Lipoprotein-Specific Phospholipid Efflux (HDL-SPE) Assay in Mice.

Molecular nutrition & food research·2026
Same author

In Reply to Inter-Instrument Imprecision Complements Bias in Evaluating LDL-C Method Performance.

Clinical chemistry·2026
Same author

Corrigendum to "Identification of a novel apoB variant in a family exhibiting hypocholesterolemia: Mechanistic insights" [J Clin Lipidol (2026) S1933-2874(26)00045-0, ahead of print].

Journal of clinical lipidology·2026

Related Experiment Video

Updated: Jul 8, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K

An improved method for estimating low LDL-C based on the enhanced Sampson-NIH equation.

Tatiana C Coverdell1, Maureen Sampson1, Rafael Zubirán2

  • 1Clinical Center, Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, USA.

Lipids in Health and Disease
|February 8, 2024
PubMed
Summary

A new enhanced Sampson-NIH (eS LDL-C) equation accurately estimates low-density lipoprotein cholesterol (LDL-C) levels. This improved accuracy helps identify more high-risk cardiovascular disease patients eligible for advanced lipid-lowering therapies like PCSK9 inhibitors.

Keywords:
BiomarkersCardiovascular diseaseCholesterolLow-density lipoproteinsTriglycerides

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.4K
Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
11:13

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Published on: May 9, 2019

8.8K

Related Experiment Videos

Last Updated: Jul 8, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.4K
Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
11:13

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Published on: May 9, 2019

8.8K

Area of Science:

  • Cardiovascular Medicine
  • Clinical Chemistry
  • Biostatistics

Background:

  • Accurate Low-density lipoprotein cholesterol (LDL-C) measurement is crucial for managing high-risk cardiovascular disease (CVD) patients.
  • Decisions regarding advanced lipid-lowering therapies, such as PCSK9 inhibitors (PCSK9i), depend on achieving sufficiently low LDL-C levels, especially when statin therapy is insufficient.

Purpose of the Study:

  • To develop and validate a novel equation for improved LDL-C estimation.
  • The new equation incorporates apolipoprotein B (apoB) alongside standard lipid panel results to enhance accuracy, particularly at lower LDL-C concentrations.

Main Methods:

  • Utilized β-quantification (BQ) as the reference standard on a large dyslipidemic cohort (N=24,406).
  • Developed the enhanced Sampson-NIH (eS LDL-C) equation using least-squares regression analysis.
  • Evaluated equation accuracy using regression parameters, mean absolute difference, Regression Error Characteristic (REC) plots, and kappa score analysis for treatment threshold categorization.

Main Results:

  • The eS LDL-C equation demonstrated superior accuracy across a broad LDL-C range compared to existing equations (e.g., Friedewald, Sampson-NIH, extended Martin).
  • eS LDL-C achieved the highest area under the curve (0.953) for LDL-C < 100 mg/dL and the best performance in categorizing patients around the 70 mg/dL threshold (kappa=0.870).
  • The eS LDL-C equation correctly reclassified approximately 80% of patients with falsely low LDL-C (<70 mg/dL) by the Friedewald equation, identifying potential candidates for PCSK9i therapy.

Conclusions:

  • The eS LDL-C equation serves as a more accurate confirmatory test for LDL-C.
  • Its improved accuracy enhances the identification of high-risk CVD patients who may benefit from advanced lipid-lowering therapies but are currently misclassified due to standard equation limitations.